Peripheral Perfusion After UNIFUZOL® Versus Lactated Ringer's in Resolving Septic Shock (UNIRING-OBS SH)

Prospective Multicenter Observational Comparative Cohort Study of Actual UNIFUZOL® (Arginine Sodium Succinate) Versus Lactated Ringer's Use in Adults With Urinary- or Pulmonary-Source Sepsis During the Early Stabilization/Resolving Phase of Septic Shock and Documented Lower-Extremity Atherosclerotic Disease: Peripheral Perfusion, NIRS Vascular Reactivity, and Macro-Microhemodynamic Coherence

Peripheral Perfusion After UNIFUZOL® Versus Lactated Ringer's in Resolving Septic Shock

Study Overview

Status

Not yet recruiting

Study Type

Observational

Enrollment (Estimated)

60

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Alexey Kovalenko, Doc Biol Sci
  • Phone Number: 212 +78127108225
  • Email: science@polysan.ru

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adults treated in participating intensive care units for urinary- or pulmonary/respiratory-source sepsis with current or recently documented septic shock, documented lower-extremity atherosclerotic peripheral artery disease, early hemodynamic stabilization, ongoing hypoperfusion, and PiCCO Plus already in place for clinical indications. Potentially eligible participants are screened consecutively during active recruitment periods.

Description

Inclusion Criteria:

  • Age 18 years or older.
  • Septic shock by Sepsis-3 currently or documented within the previous 24 hours.
  • Urinary or pulmonary/respiratory suspected or confirmed infection source.
  • Documented atherosclerotic disease of the lower-extremity arteries.
  • Mean arterial pressure at least 65 mm Hg with norepinephrine less than 0.2 micrograms/kg/min and no increase greater than 20 percent or new vasopressor during the previous 30 minutes.
  • PiCCO Plus already installed for clinical indications and technically usable.
  • At least one ongoing sign of hypoperfusion or microcirculatory dysfunction defined in the protocol.
  • Before any study-specific baseline procedure, the treating physician has independently decided that an additional crystalloid infusion is clinically indicated and has selected UNIFUZOL® or lactated Ringer's solution.
  • Thenar NIRS-VOT can be performed safely.
  • Informed consent or another ethics-board-approved consent process is completed before study-specific procedures.

Exclusion Criteria:

  • Hemorrhagic, cardiogenic, or obstructive shock as the leading cause of instability.
  • Rapidly increasing vasopressor requirement or need for immediate hemodynamic rescue inconsistent with the protocol-defined stabilization phase.
  • Clinically important fluid overload/pulmonary edema for which the treating physician considers additional fluid contraindicated; severe unstable ARDS.
  • Active major bleeding or another condition requiring urgent therapy that prevents standardized baseline assessment.
  • Expected survival less than 24 hours or limitation of intensive treatment.
  • Pregnancy or breastfeeding.
  • Participation in an interventional study expected to materially affect hemodynamics.
  • Contraindication to any component of the physician-selected fluid.
  • Upper-limb ischemia, severe Raynaud phenomenon, local thenar skin injury, or another condition making NIRS-VOT unsafe or uninterpretable.
  • Core temperature below 34 degrees Celsius.
  • Acute/critical lower-extremity ischemia requiring urgent vascular treatment or severely compromising peripheral assessments.
  • Unable to establish Tdecision/T0 or obtain pre-infusion baseline CRT; inability to obtain pre-infusion ReOx excludes the participant from the key NIRS analysis.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: CASE_CONTROL
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
UNIFUZOL® exposure cohort

Participants for whom the treating physician independently selected and actually started UNIFUZOL® at T0. The protocol does not determine indication, dose, rate, duration, repeat administration, or subsequent fluids.

Lactated Ringer's exposure cohort

Participants for whom the treating physician independently selected and actually started lactated Ringer's solution at T0. The protocol does not determine indication, dose, rate, duration, repeat administration, or subsequent fluids.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Capillary Refill Time at 6 Hours
Time Frame: 6 hours after start (window ±60 minutes)

Capillary refill time (CRT) in seconds measured using a standardized distal-finger technique. Two valid measurements are averaged; if they differ by more than 1.0 second, a third measurement is obtained and the median of three is used. The primary statistical comparison adjusts for strictly pre-infusion CRT and prespecified baseline covariates. Lower CRT is considered physiologically favorable.

6 hours after start (window ±60 minutes)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Thenar NIRS Reoxygenation Slope at 6 Hours
Time Frame: 6 hours after start (window ±60 minutes)

Post-occlusion reoxygenation slope (ReOx) derived from a standardized thenar near-infrared spectroscopy vascular occlusion test using a frozen common device/software/analysis algorithm. ReOx is analyzed continuously in percent StO2 per second and adjusted for pre-infusion ReOx. Higher ReOx is considered physiologically favorable.

6 hours after start (window ±60 minutes)
Sustained Macro-Microhemodynamic Coherent Response
Time Frame: 6 and 12 hours after start

Protocol-defined supportive composite outcome. This measure is reported as a single binary value (Yes/No), which is considered achieved only if ALL of the following criteria are simultaneously met: full macrohemodynamic stability, peripheral/microvascular recovery, and pulmonary/volume safety at both 6 and 12 hours. The composite is not a validated diagnostic criterion and is analyzed as supportive/exploratory.

6 and 12 hours after start
Change in Capillary Refill Time Over 24 Hours
Time Frame: From start through 24 hours

Serial CRT at 60 minutes, approximately 2 hours/end of infusion, 6 hours, 12 hours, and 24 hours; analyses include continuous change and trajectory models.

From start through 24 hours
Change in ReOx
Time Frame: From pre-infusion baseline through 24 hours

Serial ReOx from standardized NIRS-VOT.

From pre-infusion baseline through 24 hours
Change in De-oxygenation slope
Time Frame: From pre-infusion baseline through 24 hours

DeOx from standardized NIRS-VOT (%/min).

From pre-infusion baseline through 24 hours
Change in NIRS Vascular Reactivity Over 24 Hours (tissue oxygenation)
Time Frame: From pre-infusion baseline through 24 hours

Tissue oxygenation variables (%)

From pre-infusion baseline through 24 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: K.M. Lebedinsky, North-Western State Medical University named after I.I.Mechnikov
  • Principal Investigator: I. S. Simutis, Adult Intensive Care Unit, L.G. Sokolov North-Western District Scientific and Clinical Center, FMBA of Russia, St Petersburg, Russian Federation
  • Principal Investigator: A.Yu. Yakovlev, City Hospital No. 38 named after N.A. Semashko

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 16, 2026

Primary Completion (Estimated)

November 1, 2028

Study Completion (Estimated)

December 1, 2028

Study Registration Dates

First Submitted

September 21, 2026

First Submitted That Met QC Criteria

November 17, 2026

First Posted (Actual)

November 19, 2026

Study Record Updates

Last Update Posted (Actual)

November 19, 2026

Last Update Submitted That Met QC Criteria

November 17, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe